Dynavax Technologies | Beneficio Operativo



Operating Profit Cambio Fecha
AbbVie USD 5.72B 1.98B 2025-06
Adma Biologics USD 37.08M 2.56M 2024-12
Amgen USD 2.66B 1.37B 2025-06
AstraZeneca USD 3.51B 166M 2025-06
Biogen USD 851.8M 540.6M 2025-06
BioMarin Pharmaceutical USD 276.89M 52.99M 2025-06
Bristol-Myers Squibb USD 3.77B 366M 2025-06
Dynavax Technologies USD 10.86M 34.49M 2025-06
Gilead Sciences USD 2.7B 467M 2025-06
Glaxosmithkline GBP 702M 513M 2024-12
Merck USD 6.36B 494M 2025-06
Neurocrine Biosciences USD 145.6M 121.9M 2025-06
Novartis USD 4.86B 201M 2025-06
Pfizer USD 2.6B 1.06B 2025-06
Regeneron Pharmaceuticals USD 1.08B 487.8M 2025-06
Roche Holding CHF 4.39B 1.04B 2024-12
Sarepta Therapeutics USD 115.58M 415.96M 2025-06
TG Therapeutics USD 34.84M 26.22M 2025-06
Vertex Pharmaceuticals USD 1.15B 123.1M 2025-06


Dynavax Technologies Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.